Clinical Trial Update: Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

Phase I trial update of BAY 80-6946 (buparlisib) with paclitaxel in patients with advanced cancer; the study has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BAY 80-6946 (buparlisib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED